Notwithstanding encouraging clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial difficulty from managed care entities. Such organizations are typically building barriers to reimbursement, such as significant cost criteria and approval processes that restrict … Read More